Pseudomembranous Colitis
10
0
0
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
40%
4 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (10)
Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Addition of Lactobacillus to Metronidazole in Treatment of CDAD
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
Response of Clostridium Difficile Infection to Metronidazole Therapy
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody
Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea